JP2018520182A5 - - Google Patents

Download PDF

Info

Publication number
JP2018520182A5
JP2018520182A5 JP2018501348A JP2018501348A JP2018520182A5 JP 2018520182 A5 JP2018520182 A5 JP 2018520182A5 JP 2018501348 A JP2018501348 A JP 2018501348A JP 2018501348 A JP2018501348 A JP 2018501348A JP 2018520182 A5 JP2018520182 A5 JP 2018520182A5
Authority
JP
Japan
Prior art keywords
composition
carcinoma
hydroxyvitamin
breast
vitamin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2018501348A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018520182A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2016/042202 external-priority patent/WO2017011623A1/en
Publication of JP2018520182A publication Critical patent/JP2018520182A/ja
Publication of JP2018520182A5 publication Critical patent/JP2018520182A5/ja
Pending legal-status Critical Current

Links

JP2018501348A 2015-07-14 2016-07-14 乳房障害を処置するための経乳頭方法及び組成物 Pending JP2018520182A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562192505P 2015-07-14 2015-07-14
US62/192,505 2015-07-14
PCT/US2016/042202 WO2017011623A1 (en) 2015-07-14 2016-07-14 Transpapillary methods and compositions for treating breast disorders

Publications (2)

Publication Number Publication Date
JP2018520182A JP2018520182A (ja) 2018-07-26
JP2018520182A5 true JP2018520182A5 (cg-RX-API-DMAC7.html) 2019-08-29

Family

ID=57757662

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018501348A Pending JP2018520182A (ja) 2015-07-14 2016-07-14 乳房障害を処置するための経乳頭方法及び組成物

Country Status (7)

Country Link
US (1) US20180200206A1 (cg-RX-API-DMAC7.html)
EP (1) EP3322406A4 (cg-RX-API-DMAC7.html)
JP (1) JP2018520182A (cg-RX-API-DMAC7.html)
CN (1) CN108024959A (cg-RX-API-DMAC7.html)
AU (1) AU2016294526A1 (cg-RX-API-DMAC7.html)
CA (1) CA2992282A1 (cg-RX-API-DMAC7.html)
WO (1) WO2017011623A1 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015109391A1 (en) 2014-01-24 2015-07-30 Children's Hospital Of Eastern Ontario Research Institute Inc. Smc combination therapy for the treatment of cancer
EP3283061A4 (en) * 2015-04-14 2019-04-17 Atossa Genetics Inc. COMPOSITIONS AND METHODS FOR THE TREATMENT OF BREAST DISEASES AND ORGANISM-RELATED ILLNESSES
EP3679061A4 (en) * 2017-09-06 2021-06-09 University of Cincinnati METHOD OF PREDICTING BREAST LESIONS IN EARLY STAGE
EP3681491A4 (en) 2017-09-11 2021-06-30 Atossa Therapeutics, Inc. PROCESS FOR MANUFACTURING AND USE OF ENDOXIFES
CN110221068B (zh) * 2018-03-02 2020-09-18 中国医学科学院基础医学研究所 检测Kyn含量的试剂的应用
WO2021003433A1 (en) 2019-07-03 2021-01-07 Atossa Therapeutics, Inc. Sustained release compositions of endoxifen

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6881548B2 (en) * 1997-05-23 2005-04-19 A&G Pharmaceutical, Inc. Methods and kits for diagnosing tumorigenicity and determining resistance to the antineoplastic effects of antiestrogen therapy
US6638727B1 (en) * 1999-01-26 2003-10-28 Cytyc Health Corporation Methods for identifying treating or monitoring asymptomatic patients for risk reduction or therapeutic treatment of breast cancer
US6398765B1 (en) * 1999-03-01 2002-06-04 Pro Duct Health, Inc. Apparatus, methods and kits for simultaneous delivery of a substance to multiple breast milk ducts
US20020117169A1 (en) * 2001-02-27 2002-08-29 Kurz Daniel R. Cover and applicator for a portion of a mammalian body
JP2004530659A (ja) * 2001-02-28 2004-10-07 ジャイルズ,ブライアン,シー. 抗腫瘍および抗転移作用のための方法および処方
DE60322191D1 (de) * 2002-03-19 2008-08-28 Cytyc Corp Intraduktale behandlung von brustläsionen umfassend therapeutische und diagnostische mittel
US9808471B2 (en) * 2003-04-16 2017-11-07 Mylan Specialty Lp Nasal pharmaceutical formulations and methods of using the same
KR100419298B1 (ko) * 2003-07-28 2004-02-18 조규학 부착형 브래지어 및 그 제조방법
US7229420B2 (en) * 2003-12-23 2007-06-12 Cytyc Corporation Medical instrument for accessing a breast duct for performing a medical procedure
US20050142315A1 (en) * 2003-12-24 2005-06-30 Desimone Joseph M. Liquid perfluoropolymers and medical applications incorporating same
IL177006A0 (en) * 2005-08-02 2006-12-10 Veridex Llc Predicting bone relapse of breast cancer
WO2007067773A2 (en) * 2005-12-09 2007-06-14 Mayo Foundation For Medical Education And Research Assessing outcomes for breast cancer patients by determining cyp2d6 genotype
ES2539042T3 (es) * 2006-06-02 2015-06-25 Glaxosmithkline Biologicals S.A. Procedimiento de identificación de si un paciente será respondedor o no a inmunoterapia
PT2101731T (pt) * 2006-11-21 2018-04-18 Jina Pharmaceuticals Inc Endoxifeno para utilização no tratamento de cancro
CA2673870A1 (en) * 2006-12-27 2008-07-10 Emory University Compositions and methods for the treatment of infections and tumors
WO2009105640A1 (en) * 2008-02-22 2009-08-27 Virginia Commonwealth University Signatures associated with rejection or recurrence of cancer
WO2010008427A1 (en) * 2008-04-11 2010-01-21 Ludwig Institute For Cancer Research Ltd. Tryptophan catabolism in cancer treatment and diagnosis
WO2009129352A2 (en) * 2008-04-15 2009-10-22 Windy Hill Medical Device and method for accessing and treating ducts of mammary glands
WO2010009335A1 (en) * 2008-07-17 2010-01-21 Micell Technologies, Inc. Drug delivery medical device
ES2624557T3 (es) * 2008-12-11 2017-07-14 Besins Healthcare Luxembourg Sarl Composiciones farmacéuticas transdérmicas que comprenden un SERM
WO2011072244A1 (en) * 2009-12-10 2011-06-16 Mount Sinai School Of Medicine Of New York University Method of treatment of breast cancer with tamoxifen
EP2425833A1 (de) * 2010-09-03 2012-03-07 Fresenius Kabi Deutschland GmbH Die intravenöse Applikation von Fischöl/DHA +EPA vor bzw. mit Beginn der Chemotherapie
US20130045179A1 (en) * 2011-08-15 2013-02-21 Mihai Ciustea Combination therapy and methods for treatment and prevention of hyperproliferative diseases
US9517183B2 (en) * 2012-01-30 2016-12-13 Patrick B. Ward Nipple abrasion protector
WO2013134230A1 (en) * 2012-03-05 2013-09-12 Xavier University Boron-based 4-hydroxytamoxifen and endoxifen prodrugs as treatment for breast cancer
US9220680B2 (en) * 2012-07-13 2015-12-29 South Dakota State University Compositions and methods for localized drug delivery through mammary papillae
EP3092027A4 (en) * 2014-01-10 2017-09-06 Atossa Genetics Inc. Transpapillary methods and compositions for diagnosing and treating breast conditions
EP3283061A4 (en) * 2015-04-14 2019-04-17 Atossa Genetics Inc. COMPOSITIONS AND METHODS FOR THE TREATMENT OF BREAST DISEASES AND ORGANISM-RELATED ILLNESSES

Similar Documents

Publication Publication Date Title
US11730736B2 (en) Anticancer agents
KR102566461B1 (ko) 조합 요법
US20260137817A1 (en) Combination cancer immunotherapy with pentaaza macrocyclic ring complex
RS65214B1 (sr) Modulatori integrisanog puta stresa
US12414934B2 (en) Combination therapies
US12551581B2 (en) Combination cancer immunotherapy with pentaaza macrocyclic ring complex
RU2017104909A (ru) Лечение рака комбинацией лучевой терапии, наночастиц оксида церия и химиотерапевтического средства
SG174419A1 (en) Methods of treatment using combination therapy
JP2017516802A5 (cg-RX-API-DMAC7.html)
BR112020015520A2 (pt) terapia de combinação para câncer com complexo de anel macrocíclico pentaaza e agente anticâncer à base de platina
US9512138B2 (en) Compositions and methods for treating cancer
JP6422936B2 (ja) 5−ブロモ−インジルビン
US20160128988A1 (en) Combinations for the treatment of cancer comprising a mps-1 kinase inhibitor and a mitotic inhibitor
TWI837231B (zh) 含有ezh1/2雙重抑制劑之醫藥組合及其用途
JP5694782B2 (ja) 肺癌、腺癌及び他の病状のための治療方法及び組成物
CN111773388B (zh) A-失碳-5α雄甾烷化合物类药物与抗癌药物的联合应用
EP4601643A1 (en) Composition for treating paclitaxel-resistant breast cancer and method for preparation thereof
HK40060452A (en) COMBINED USE OF A-NOR-5α ANDROSTANE COMPOUND DRUG AND ANTICANCER DRUG